TerminatedNot Applicable

Intermetatarsal Bursitis in Patients With Rheumatoid Arthritis

Stopped: The study was stopped due to health-related issues in the research group, that hindered inrolement of patients.

Denmark3 participantsStarted 2023-01-18

Plain-language summary

The aim of the study is to investigate the incidence and clinical implications of intermetatarsal bursitis (IMB) in patients with rheumatoid arthritis (RA). The hypothesis is that IMB is a cause of pain in patients with RA.

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Age \> 18 years * Forefoot pain and diagnosed with RA (patient group) * Diagnosed with an axial arthritis (control group) Exclusion Criteria: * Age \<18 years * Open wounds or ongoing infection in the forefoot at the time of examination * Persons with a history of significant trauma in the forefoot, e.g. any fracture or previous surgeries in the forefoot * Persons who have previously received intermetatarsal treatment (Morton's neuroma or IMB) in the same foot, e.g. injection within 6 months or operation at any time * Exclusion from MRI scan only: * Persons with contraindications to participate in MRI scan * Persons with severely impaired renal function (GFR \<30 ml/min)

What they're measuring

Incidence of intermetatarsal bursitis on MRI

Timeframe: 8 weeks

Incidence of intermetatarsal bursitis on US

Timeframe: 8 weeks

Incidence of other pathology on MRI

Timeframe: 8 weeks

Incidence of other pathology on US

Timeframe: 8 weeks

Change in Visual Analogue Score (VAS) score

Timeframe: At inclusion, 1 and 3 month(s) post treatment

Trial details

NCT IDNCT05698563

SponsorRigshospitalet, Denmark

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2023-02-14

View on ClinicalTrials.gov More Intermetatarsal Bursitis trials